Empirical antibiotic therapy in febrile patients with neutropenia and malignant disease.
D000380:Agranulocytosis / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D002228:Carbenicillin / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D003016:Clostridium perfringens / Q000302:isolation & purification; D004359:Drug Therapy, Combination; D004926:Escherichia coli / Q000302:isolation & purification; D005334:Fever / Q000209:etiology; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000150:complications*; D011113:Polymyxins / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D011339:Probenecid / Q000627:therapeutic use; D011549:Pseudomonas; D013210:Staphylococcus / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D011113:Polymyxins; D002981:Clindamycin; D002228:Carbenicillin; D011339:Probenecid; D002512:Cephalothin; D011188:Potassium